Advertisement
Singapore markets close in 3 hours 2 minutes
  • Straits Times Index

    3,442.78
    -28.38 (-0.82%)
     
  • Nikkei

    40,057.63
    -68.72 (-0.17%)
     
  • Hang Seng

    17,428.68
    -349.73 (-1.97%)
     
  • FTSE 100

    8,204.89
    +17.43 (+0.21%)
     
  • Bitcoin USD

    64,211.40
    -593.53 (-0.92%)
     
  • CMC Crypto 200

    1,331.40
    +1.90 (+0.14%)
     
  • S&P 500

    5,544.59
    -43.68 (-0.78%)
     
  • Dow

    40,665.02
    -533.08 (-1.29%)
     
  • Nasdaq

    17,871.22
    -125.68 (-0.70%)
     
  • Gold

    2,426.50
    -29.90 (-1.22%)
     
  • Crude Oil

    82.27
    -0.55 (-0.66%)
     
  • 10-Yr Bond

    4.1890
    -4.1460 (-49.74%)
     
  • FTSE Bursa Malaysia

    1,637.08
    +3.27 (+0.20%)
     
  • Jakarta Composite Index

    7,270.79
    -50.28 (-0.69%)
     
  • PSE Index

    6,819.61
    +114.60 (+1.71%)
     

Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

ADVERTISEMENT

Penumbra (PEN)

Headquartered in Alameda, CA, Penumbra, as a global healthcare company, designs, develops, manufactures and markets innovative products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It has a broad portfolio that addresses challenging medical conditions in markets with significant unmet needs.

PEN boasts a Growth Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 37.3% year-over-year for 2024, while Wall Street anticipates its top line to improve by 17.4%.

Five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $2.87 per share for 2024. PEN boasts an average earnings surprise of 26%.

Looking at cash flow, Penumbra is expected to report cash flow growth of 255.5% this year; PEN has generated cash flow growth of 34.7% over the past three to five years.

Investors should take the time to consider PEN for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Penumbra, Inc. (PEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research